These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 29688337)

  • 41. Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington's disease by preventing p75NTR up-regulation and astrocyte-mediated inflammation.
    Miguez A; García-Díaz Barriga G; Brito V; Straccia M; Giralt A; Ginés S; Canals JM; Alberch J
    Hum Mol Genet; 2015 Sep; 24(17):4958-70. PubMed ID: 26063761
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease.
    Beaumont V; Mrzljak L; Dijkman U; Freije R; Heins M; Rassoulpour A; Tombaugh G; Gelman S; Bradaia A; Steidl E; Gleyzes M; Heikkinen T; Lehtimäki K; Puoliväli J; Kontkanen O; Javier RM; Neagoe I; Deisemann H; Winkler D; Ebneth A; Khetarpal V; Toledo-Sherman L; Dominguez C; Park LC; Munoz-Sanjuan I
    Exp Neurol; 2016 Aug; 282():99-118. PubMed ID: 27163548
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Luteolin as potential treatment for Huntington's disease: Insights from a transgenic mouse model.
    Mohammed A; Ramadan A; Elnour AA; Saeed AAAM; Al Mazrouei N; Alsulami FT; Alqarni YS; Menon V; Amoodi AA; Abdalla SF
    CNS Neurosci Ther; 2024 Sep; 30(9):e70025. PubMed ID: 39228080
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Corticosterone dysregulation exacerbates disease progression in the R6/2 transgenic mouse model of Huntington's disease.
    Dufour BD; McBride JL
    Exp Neurol; 2016 Sep; 283(Pt A):308-17. PubMed ID: 27381424
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reductions in behavioral deficits and neuropathology in the R6/2 mouse model of Huntington's disease following transplantation of bone-marrow-derived mesenchymal stem cells is dependent on passage number.
    Rossignol J; Fink KD; Crane AT; Davis KK; Bombard MC; Clerc S; Bavar AM; Lowrance SA; Song C; Witte S; Lescaudron L; Dunbar GL
    Stem Cell Res Ther; 2015 Feb; 6(1):9. PubMed ID: 25971780
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington's disease.
    Di Pardo A; Amico E; Basit A; Armirotti A; Joshi P; Neely MD; Vuono R; Castaldo S; Digilio AF; Scalabrì F; Pepe G; Elifani F; Madonna M; Jeong SK; Park BM; D'Esposito M; Bowman AB; Barker RA; Maglione V
    Sci Rep; 2017 Jul; 7(1):5280. PubMed ID: 28706199
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Modulation of nucleosome dynamics in Huntington's disease.
    Stack EC; Del Signore SJ; Luthi-Carter R; Soh BY; Goldstein DR; Matson S; Goodrich S; Markey AL; Cormier K; Hagerty SW; Smith K; Ryu H; Ferrante RJ
    Hum Mol Genet; 2007 May; 16(10):1164-75. PubMed ID: 17403718
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Embryonic Mutant Huntingtin Aggregate Formation in Mouse Models of Huntington's Disease.
    Osmand AP; Bichell TJ; Bowman AB; Bates GP
    J Huntingtons Dis; 2016 Dec; 5(4):343-346. PubMed ID: 27886014
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterization of subventricular zone-derived progenitor cells from mild and late symptomatic YAC128 mouse model of Huntington's disease.
    Silva AC; Ferreira IL; Hayden MR; Ferreiro E; Rego AC
    Biochim Biophys Acta Mol Basis Dis; 2018 Jan; 1864(1):34-44. PubMed ID: 28939435
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Disease-modifying effects of ganglioside GM1 in Huntington's disease models.
    Alpaugh M; Galleguillos D; Forero J; Morales LC; Lackey SW; Kar P; Di Pardo A; Holt A; Kerr BJ; Todd KG; Baker GB; Fouad K; Sipione S
    EMBO Mol Med; 2017 Nov; 9(11):1537-1557. PubMed ID: 28993428
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery.
    Zuccato C; Liber D; Ramos C; Tarditi A; Rigamonti D; Tartari M; Valenza M; Cattaneo E
    Pharmacol Res; 2005 Aug; 52(2):133-9. PubMed ID: 15967378
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington's disease.
    Samadi P; Boutet A; Rymar VV; Rawal K; Maheux J; Kvann JC; Tomaszewski M; Beaubien F; Cloutier JF; Levesque D; Sadikot AF
    Genes Brain Behav; 2013 Feb; 12(1):108-24. PubMed ID: 23006318
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Progressive gene dose-dependent disruption of the methamphetamine-sensitive circadian oscillator-driven rhythms in a knock-in mouse model of Huntington's disease.
    Ouk K; Aungier J; Morton AJ
    Exp Neurol; 2016 Dec; 286():69-82. PubMed ID: 27646506
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Small Molecule Pytren-4QMn Metal Complex Slows down Huntington's Disease Progression in Male zQ175 Transgenic Mice.
    Merino M; González S; Tronch MC; Sánchez-Sánchez AV; Clares MP; García-España A; García-España E; Mullor JL
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894844
    [TBL] [Abstract][Full Text] [Related]  

  • 55. N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington's disease.
    Wright DJ; Renoir T; Smith ZM; Frazier AE; Francis PS; Thorburn DR; McGee SL; Hannan AJ; Gray LJ
    Transl Psychiatry; 2015 Jan; 5(1):e492. PubMed ID: 25562842
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model.
    Squitieri F; Di Pardo A; Favellato M; Amico E; Maglione V; Frati L
    J Cell Mol Med; 2015 Nov; 19(11):2540-8. PubMed ID: 26094900
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In Vivo Multidimensional Brain Imaging in Huntington's Disease Animal Models.
    Flament J; Hantraye P; Valette J
    Methods Mol Biol; 2018; 1780():285-301. PubMed ID: 29856025
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA.
    Wang YL; Liu W; Wada E; Murata M; Wada K; Kanazawa I
    Neurosci Res; 2005 Nov; 53(3):241-9. PubMed ID: 16095740
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Transgenic animal models for study of the pathogenesis of Huntington's disease and therapy.
    Chang R; Liu X; Li S; Li XJ
    Drug Des Devel Ther; 2015; 9():2179-88. PubMed ID: 25931812
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat.
    Clemens LE; Weber JJ; Wlodkowski TT; Yu-Taeger L; Michaud M; Calaminus C; Eckert SH; Gaca J; Weiss A; Magg JC; Jansson EK; Eckert GP; Pichler BJ; Bordet T; Pruss RM; Riess O; Nguyen HP
    Brain; 2015 Dec; 138(Pt 12):3632-53. PubMed ID: 26490331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.